» Articles » PMID: 29127238

Protective Effects of the Mechanistic Target of Rapamycin Against Excess Iron and Ferroptosis in Cardiomyocytes

Abstract

Clinical studies have suggested that myocardial iron is a risk factor for left ventricular remodeling in patients after myocardial infarction. Ferroptosis has recently been reported as a mechanism of iron-dependent nonapoptotic cell death. However, ferroptosis in the heart is not well understood. Mechanistic target of rapamycin (mTOR) protects the heart against pathological stimuli such as ischemia. To define the role of cardiac mTOR on cell survival in iron-mediated cell death, we examined cardiomyocyte (CM) cell viability under excess iron and ferroptosis conditions. Adult mouse CMs were isolated from cardiac-specific mTOR transgenic mice, cardiac-specific mTOR knockout mice, or control mice. CMs were treated with ferric iron [Fe(III)]-citrate, erastin, a class 1 ferroptosis inducer, or Ras-selective lethal 3 (RSL3), a class 2 ferroptosis inducer. Live/dead cell viability assays revealed that Fe(III)-citrate, erastin, and RSL3 induced cell death. Cotreatment with ferrostatin-1, a ferroptosis inhibitor, inhibited cell death in all conditions. mTOR overexpression suppressed Fe(III)-citrate, erastin, and RSL3-induced cell death, whereas mTOR deletion exaggerated cell death in these conditions. 2',7'-Dichlorodihydrofluorescein diacetate measurement of reactive oxygen species (ROS) production showed that erastin-induced ROS production was significantly lower in mTOR transgenic versus control CMs. These findings suggest that ferroptosis is a significant type of cell death in CMs and that mTOR plays an important role in protecting CMs against excess iron and ferroptosis, at least in part, by regulating ROS production. Understanding the effects of mTOR in preventing iron-mediated cell death will provide a new therapy for patients with myocardial infarction. NEW & NOTEWORTHY Ferroptosis has recently been reported as a new form of iron-dependent nonapoptotic cell death. However, ferroptosis in the heart is not well characterized. Using cultured adult mouse cardiomyocytes, we demonstrated that the mechanistic target of rapamycin plays an important role in protecting cardiomyocytes against excess iron and ferroptosis.

Citing Articles

Ferroptosis: a potential target for non-surgical treatment of laryngeal cancer.

Luo Y, He Y, Xu S, Chen Y, Qin F, Hu W Eur Arch Otorhinolaryngol. 2025; .

PMID: 40087171 DOI: 10.1007/s00405-025-09279-y.


Vagus nerve stimulation alleviates myocardial injury following hepatic ischemia-reperfusion in rats by inhibiting ferroptosis via the activation of the SLC7A11/GPX4 axis.

Zhang P, Qin Y, Wang H, Wang J Eur J Med Res. 2025; 30(1):162.

PMID: 40075496 PMC: 11900121. DOI: 10.1186/s40001-025-02416-7.


Selenium and Selenoproteins: Mechanisms, Health Functions, and Emerging Applications.

Shahidin , Wang Y, Wu Y, Chen T, Wu X, Yuan W Molecules. 2025; 30(3).

PMID: 39942544 PMC: 11820089. DOI: 10.3390/molecules30030437.


The link between ferroptosis and autophagy in myocardial ischemia/reperfusion injury: new directions for therapy.

Yang X, Wu H, Liu D, Zhou G, Zhang D, Yang Q J Cardiovasc Transl Res. 2025; .

PMID: 39885084 DOI: 10.1007/s12265-025-10590-6.


Dapagliflozin inhibits ferroptosis to improve chronic heart failure by regulating Nrf2/HO-1/GPX4 signaling pathway.

Zhang J, Chen X, Lv S, Hao Q PLoS One. 2025; 20(1):e0317295.

PMID: 39874368 PMC: 11774390. DOI: 10.1371/journal.pone.0317295.


References
1.
Chan W, Taylor A, Ellims A, Lefkovits L, Wong C, Kingwell B . Effect of iron chelation on myocardial infarct size and oxidative stress in ST-elevation-myocardial infarction. Circ Cardiovasc Interv. 2012; 5(2):270-8. DOI: 10.1161/CIRCINTERVENTIONS.111.966226. View

2.
Jiang L, Kon N, Li T, Wang S, Su T, Hibshoosh H . Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015; 520(7545):57-62. PMC: 4455927. DOI: 10.1038/nature14344. View

3.
Barth S, Glick D, Macleod K . Autophagy: assays and artifacts. J Pathol. 2010; 221(2):117-24. PMC: 2989884. DOI: 10.1002/path.2694. View

4.
Maiorano A, Stallone G, Schena A, Infante B, Pontrelli P, Schena F . Sirolimus interferes with iron homeostasis in renal transplant recipients. Transplantation. 2006; 82(7):908-12. DOI: 10.1097/01.tp.0000235545.49391.1b. View

5.
Schriewer J, Peek C, Bass J, Schumacker P . ROS-mediated PARP activity undermines mitochondrial function after permeability transition pore opening during myocardial ischemia-reperfusion. J Am Heart Assoc. 2013; 2(2):e000159. PMC: 3647275. DOI: 10.1161/JAHA.113.000159. View